Jubilant Life Sciences Ltd, an integrated global pharmaceuticals and life sciences company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for levofloxacin tablets, 250mg and 500mg. It is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
Jubilant Life Sciences has announced that it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections, including pneumonia. The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.

